JAMA Oncology
Home » Resources » JAMA Oncology

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

“These results, combined with the patient satisfaction with the relative ease of providing blood rather than a solidtissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations.”

Bishal Gyawali, MD, PhD; Howard (Jack) West, MD

Editorial

concordanse

with tissue genotyping for targetable alterations before first-line NSCLC therapy

“These results, combined with the patient satisfaction with the relative ease of providing blood rather than a solidtissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations.”

Bishal Gyawali, MD, PhD; Howard (Jack) West, MD

Editorial

concordanse

with tissue genotyping for targetable alterations before first-line NSCLC therapy

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 can increase the likelihood of finding targetable mutations.

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 can increase the likelihood of finding targetable mutations.

Key findings

Key findings

were unable to get complete genomic results from tissue biopsy

had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)

had a response or stable disease based on RECIST criteria

of-eligible-patients

were unable to get complete genomic results from tissue biopsy

as-many-patients

had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)

of-patients

had a response or stable disease based on RECIST criteria

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Publication Date: 11/06/2018

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Publication Date: 11/06/2018

You may also be interested in…

You may also be interested in…

publication-tile_01

Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

View Publication

publication-tile_02

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

View Publication

publication-tile_01

Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

View Publication

publication-tile_02

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

View Publication

Open chat
Message us